Renee P. Tannenbaum

Renee P. Tannenbaum (board member) discloses dealings in 4 companies, chiefly Zogenix, Inc., ANI Pharmaceuticals Inc and Sharps Compliance Corp. We count 25 filings; the first trade dates from 16 March 2012 and the latest from 21 May 2026.

On the open market, the record shows 8 purchases worth €273k and 5 sales worth €1.3M. Sales outweigh purchases by €1.1M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 7 share grants and 4 option exercises.

The median purchase comes to €28k. Clusters matter here: 4 out of 5 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 10 June 2026, the filings show a share grant in ANI Pharmaceuticals Inc. The most recent open-market purchase was published on 16 December 2024, 677 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.